Plain-English translation of NCT06907056 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study compares two different HIV medication combinations in men whose virus is already well-controlled on treatment. You would either continue your current three-drug regimen (darunavir/cobicistat plus tenofovir/emtricitabine) or switch to a simpler two-drug regimen (darunavir/cobicistat plus lamivudine). Researchers want to see if the medication with fewer drugs works just as well at keeping your virus suppressed.
Taking fewer pills each day can make HIV treatment easier to stick with and may reduce side effects. This study is exploring whether this medication combination can maintain the same level of viral control with a simpler regimen.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either continue your current three-drug combination or switch to the new two-drug combination. You will have study visits at 24 weeks and again at 48 weeks, where your viral load will be checked with blood tests and your health will be monitored. Throughout the 48-week period, you will take your assigned medication as directed and report any side effects or changes in how you feel.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
Mexico